The value of a drug can be expressed as cost needed to increase a unit of health. However, summarizing the economic value of a molecule with multiple indications is a complex process. The COVET study was conducted to facilitate a comprehensive economic evaluation of adalimumab across all approved indications. METHODS: An algorithm was developed to estimate the total economic value of adalimumab. This value was calculated as the sum of the incremental cost-utility ratios for treating rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, and psoriasis from a Italian National Health Care (NHC) perspective. Estimates of the cost per quality-adjusted life year (QALY) gained by using adalimumab instead of standard therapy were derived from previously developed economic models. The sum was weighted by the prevalence of each of the diseases considered. Through a systematic literature review, the cost per QALY gained by using other anti-TNF drugs was extrapolated. Subsequently, a Boston matrix was developed to establish the relationship between demand and health supply. A one-way sensitivity analysis (SA) performed to assess the robustness of the results. RESULTS: The total economic value of adalimumab in Italy amounted to €34,750 per QALY. The sensitivity analysis showed a cost per QALY gained ranging between €27,447 and €40,412. The analysis of the Boston matrix indicated that, with the exception of psoriasis, the cost per QALY gained by using adalimumab instead of standard therapy was below the common WTP threshold. In comparison with innovative molecules, the total economic value of adalimumab was positive and sustainable. CONCLUSIONS: This study provides an estimate of the cost-effectiveness of adalimumab across all approved indications that is below the threshold value for health care interventions. The results should encourage decision makers to facilitate patient access to this cost-effective treatment. They may also promote research to develop innovative molecules that are even more cost-effective.
OBJECTIVES:
As treatments trend towards personalized medicine for conditions with certain genetic expressions, new opportunities exist for diagnostic tests to change the standard of care and demonstrate positive economic impact to payers. A systematic review of the role of economic evaluation to the coverage and payment of novel diagnostics has not yet been performed. The authors undertook this analysis to examine what evidence exists to document the use of health economic rationale and modeling to impact reimbursement and market access outcomes for diagnostics. METHODS: A systematic review of published literature related to the reimbursement and health technology assessment of diagnostics was conducted. In addition, published coverage policies and HTAs in the US, UK, and Germany related to personalized medicine diagnostics commercialized within the last decade were reviewed. Policies and HTAs were graded to document the level of impact economics played to decision-outcomes, if reported. Where specific references were not made, a review of the citations referenced was conducted to see if economic papers or models were included within their decision-framework. RESULTS: Most published personalized medicine diagnostic coverage policies and HTAs reference both clinical and economic evidence, though clinical data is prioritized. Of the policies analyzed, national HTA groups that reviewed novel diagnostics or products with companion diagnostics, were most explicit in their consideration of clinical and economic data. US payers were less likely to explicitly reference economic data. CONCLUSIONS: As treatments are becoming more and more dependent on companion diagnostic tests to influence treatment of disease in a variety of subgroups, the processes by which diagnostics are approved, covered, and reimbursed will become more scrutinized. More standardized and transparent incorporation of economic rationale and modeling into payer coverage, payment, and HTA evaluation processes would clarify expectations and help companies plan for HEOR activities.
PHP21 HOW WILL THE NEW NHS DECENTRALISED REFORMS IMPACT ON ACCESS TO MEDICINES IN ENGLAND?
Assimakopoulos M, White R Access Partnership, London, UK OBJECTIVES: With the formation of Clinical Commissioning Groups (CCGs) GP Practices will come together to commission services for their local populations. However, freedoms to be delegated from the Clinical Commissioning board may mean that considerable 'command and control' will still be exerted from the centre. Secondary and primary research was undertaken to gain insight into how devolved locality based commissioning is likely to impact on access to medicines. METHODS: We reviewed 35 first wave CCGs in terms of population coverage, financial stability and current Primary care Trust (PCT) activities in relation to Practice based commissioning. We then interviewed 5 NHS Experts to assess whether these CCGs would be allowed the aspirational freedoms referred to in the 2012 Health and Social Care Act-in particular prescribing freedoms formerly under the guidance of PCTs. Various information sources were used Care Quality Commission, Audit Commission, and Health Select Committee reports to support the interpretation of the findings. RESULTS: The selected CCGs represented an homogeneous group of practices in that they had previously demonstrated financial stewardship and collaborative working with their 'host' PCTs. Many CCGs had been devolved the Commissioning budget by their PCTs and were routinely involved in setting up medicines management protocols with their provider hospitals. Almost half of the CCGs had coterminous medicines management contracts shared with their PCTs. NHS experts raised issues around corporate and clinical governance and how practices would fundamentally want to take on the devolved financial responsibilities. CONCLUSIONS: The NHS reforms mean that £60 Billion of the total health care budget will be under the control of CCGs. PCTs and Strategic Health Authorities will be abolished and with a watered down role for NICE postcode variation may be rife; access to medicines will continue to be fraught with many layers of decision making and further delays.
PHP22 PHARMACOVIGILANCE IN QATAR -A PHARMACIST SURVEY
Wilbur K Qatar University, Doha, Qatar OBJECTIVES: Active domestic pharmacovigilance programs are necessary as adverse drug reaction (ADR) data from other countries may overlook safety patterns in local populations. The success of any surveillance system relies upon active participation of reporters. The objective of this study was to describe pharmacist reporting of suspected ADRs in Qatar to inform policy recommendations to the Supreme Council of Health. METHODS: A 27-item survey was developed following comprehensive literature review of relevant published research. Questions encompassed broad domains including: pharmacist knowledge of and experiences in reporting suspected ADRs; attitudes towards health professional pharmacovigilance roles; perceived barriers and facilitators to reporting; and recommendations for improvements in this process. The web-based survey was formatted for electronic delivery and response for self-administration in English or Arabic by a convenience sample of over 500 Qatar pharmacists. RESULTS: The survey remained open for two months between April 30 and June 30, 2011. Of the 142 (25%) total responses, 116 (81.6%) surveys were completed beyond demographic data and included information about prior suspected ADR reporting experiences. Knowledge of ADR terminology and reporting purpose among the 116 (20%) responding pharmacists was high, but only 34 (30%) had ever made a suspected ADR report in Qatar. Most respondents expressed positive attitudes towards pharmacist roles in pharmacovigilance activities, but inability to recognize a potential ADR or subsequently access a reporting form were perceived barriers, with enhanced training and efficiency in report submission corresponding identified facilitators to future participation. Hospital pharmacists were 7 times more likely than ambulatory-care based pharmacists to have reported a suspected ADR in Qatar. CONCLUSIONS: Pharmacists in Qatar are willing to engage in pharmacovigilance activities if supported by increased training and transparency in the reporting process. A national infrastructure with capacity to collect and manage suspected ADR reports and promote patient and medication safety is exigent.
PHP23 THE EARLY BENEFIT ASSESSMENT OF NEW PHARMACEUTICALS IN GERMANY ("AMNOG"): A STRUCTURED SURVEY ANALYSIS ONE YEAR AFTER ENACTMENT
Stoeckel F 1 , Neubauer AS 2 1 University of Bayreuth, Bayreuth, Germany, 2 IfG Institute for Health Economics, München, Germany OBJECTIVES: In January 2011, the act for restructuring the pharmaceutical market ("AMNOG") was introduced in Germany. We analyzed the effects one year after AMNOG's implementation in an empirical study. The research focused on surveying affected stakeholders, systematically summarizing their experiences, and identifying topics of controversy. METHODS: Stakeholders were defined based on statements during the AMNOG legislation: Payors, Pharmaceutical Industry, National Regulatory Bodies, Scientific Experts, Patients, Care Providers, Politicians, Pharmacies and External Service Providers. The benefit assessement process was structured into 6 topics: Market Launch, Early Benefit Assessment, Price Negotiations, Arbitration Procedure, Cost-Benefit Analysis and Process. 45 experts participated in the structured survey (26% response rate), which consisted of closed questions supplemented by optional open-ended questions (total 47 items). Descriptive statistical and dissimilarity analyses were performed. RESULTS: Between the 9 stakeholder groups, several items were highly controversial: negotiation position of statutory health insurances ("GKV-Spitzenverband") in rebate level negotiations (distance index L 2 ϭ1.17), use of European price reference in the arbitration process (L 2 ϭ1.08) and several others such as transparency of the benefit assessment process (L 2 ϭ0.95). Different response profiles were observed between stakeholders but they yielded relatively low dissimilarities on cost-benefit assessment.
Overall, the topic areas "Market Launch", "Price Negotiations" and "Process" were most controversial. Regarding stakeholder groups, those experts belonging to Pharmaceutical industry displayed the largest differences to those of the Payor group. 16 experts answered the open-ended question about "costs of dossier process" ranging between €100,000 and €500,000 per drug assessed. CONCLUSIONS:
We performed a structured survey analysis with experts to assess the new German benefit assessement process based on their one year experience. Several topics and items of high controversy between the affected stakeholders were identified. However, due to the limited quantitative outcomes experience with the AMNOG process to date future research is needed to increase our knowledge about the legislation.
PHP24 SHOULD PHARMACIST REMUNERATION SYSTEMS IN EUROPE BE REFORMED IN ORDER TO INCREASE GENERIC MEDICINE DISPENSING?
Dylst P 1 , Vulto A 2 , Simoens S 3 1 KU Leuven, Leuven, Vlaams Brabant, Belgium, 2 Erasmus University Medical Center, Hospital Pharmacy, Rotterdam, The Netherlands, 3 Katholieke Universiteit Leuven, Leuven, Vlaams Brabant, Belgium OBJECTIVES: The use of generic medicines, which can generate large savings to health care budgets, should be supported by incentives on both the supply side and the demand side. Pharmacists' remuneration can influence the choice of the dispensed drug. The aim of this study is to provide an overview of different pharmacist remuneration systems for generic medicines in Europe, with a view to exploring how pharmacist remuneration systems can contribute to generic medicine dispensing. METHODS: Data were obtained from a literature review, a Master thesis in Pharmaceutical Care at the University of Leuven and a mailing sent to all members of the Pharmaceutical Group of the European Union with a request for information about the local remuneration systems of community pharmacists and the possible existence of reports on discounting practices. RESULTS: Pharmacists' remuneration in most European countries consists of the combination of a fixed fee per item and a certain percentage of the acquisition cost or the delivery price of the medicines. This percentage component can be fixed, regressive or capped for very high-cost medicines and acts as a disincentive for dispensing generic medicine. Information on discounting for generic medicines, which is common practice in several European countries, tends to be confidential. Data showed that discounts varied from 10% to 70% of the wholesale selling price. CONCLUSIONS: Pharmacists should not be financially penalized for dispensing generic medicines. Therefore, their remuneration should move towards a fee-for-performance remuneration instead of a price-dependent reimbursement which is currently used in many European countries. Such a fee-for-performance remuneration system provides a stimulus for generic medicines dispensing as pharmacists are not penalized for dispensing generic medicines. More and more European countries are moving towards such a remuneration system. Pharmacists' remuneration systems also need to account for the loss of income to pharmacists from prohibiting discounting practices.
PHP25 THE PHARMACEUTICAL INDUSTRY AS PARTNER IN INTEGRATED CARE CONTRACTS -POTENTIAL IMPROVEMENT OR VAIN ATTEMPT? FIRST EXPERIENCES FROM GERMANY
Chase DP 1 , Amelung VE 2 1 Institute for Applied Health Services Research, Berlin, Berlin, Germany, 2 Hannover Medical School, Hannover, Germany, Germany OBJECTIVES: After the Pharmaceutical Market Restructuring Act (AMNOG) took effect in 2010, almost all pharmaceutical companies consider how to position themselves differently in health care related value chains. The law offers new options for the pharmaceutical and medical devices industry to reorganize their business models in order to become an active and equal partner in integrated care contracts with insurance companies. This paper examines key success factors for collaborating with other stakeholders. METHODS: Due to the distinctiveness and topicality of integrated care contracts, four cases of selective contracting between the industry and insurance companies were scrutinized. On this basis, experts of all parties (pharmaceutical industry, health care providers, insurance companies, and management companies) were interviewed. RESULTS: Whereas insurance companies and health care providers, as well as health care providers and the pharmaceutical industry have gained experience in cooperating with each other (e.g., in clinical trials), fears of contacts between insurance companies and the pharmaceutical industry still exist. They need to be abolished by establishing capable structures and a bi-lateral willingness to cooperate. Pivotal elements of selective contracting can be allocated to four segments, namely markets (exceed certain thresholds such as number of patients enrolled), products (targeting of "real" care-gaps and physicians' relief), management (distribution of tasks, evaluation concepts), and financial mechanisms (gain-sharing as means to achieve revenue and profitability). First experiences in Germany have proofed technologybased contracts to be suitable for inexperienced companies to start with. The level of complexity of selective contracts and the timely component are often underestimated. CONCLUSIONS: Pilot projects are now being implemented into practice which underpins their topicality and the importance of adequate evaluation. Their success depends on the inclusion of relevant partners and the intelligent combination of the stakeholders' various strengths. The objective is to develop concepts which are applicable outside of Germany on international markets.
PHP26

REGISTRIES OF MEDICAL DEVICES IN THE EUROPEAN UNION
Niederländer CS, Wahlster P, Kriza C, Schaller S, Kolominsky-Rabas P University of Erlangen-Nuremberg, Erlangen, Germany OBJECTIVES: In early 2012, there were a number of serious events in the implant area. A recent example are the defective breast implants of the French company Poly Implant Prothese. The second incident concerns 'metal on metal' (MoM) hip implants. These events raised public awareness and started a scientific discussion in academia and politics on safety issues and monitoring medical devices. Apparently, there is a big lack in the surveillance of medical devices. Therefore, the objective of this work is to detect existing implant registries in the European Union. METHODS: A systematic review of the literature was carried out to identify different types of implant registries in the European Union Member States (EU MS). The systematic search for implant registries was performed in the databases PubMed, Medline, CRD York. All results up to April 2012 were considered. RESULTS: Ninetynine registries in the EU MS for different types of implants were identified. As demonstrated, most registries exist in the field of cardiac implants and arthroplasty (34 and 30 within Europe). The distribution of implant registries showed variation in the different EU MS. For a lot of implant categories, none or very few registries could be identified. Some countries run more registries than others (UK 15, Portugal 1). CONCLUSIONS: The results show that there is only a limited number of reviews on registries and a centralized monitoring system in the EU MS is missing. Our results reveal a lack of transparency concerning number, aim, structure and quality of registries. This is crucial, as registries work as an early warning systems for identifying and notifying patients at risk. [The research is supported by the German Federal Ministry of Education and Research (BMBF), project grant No. 01EX1013B as part of the Centre of Excellence for Medical Technology]. Novartis Hungary, Budapest, Hungary OBJECTIVES: Transparency Directive (TD) (89/105/EEC) aims to foster the transparency of measures regulating the pricing and reimbursement decisions of pharmaceuticals in European Union Member States. TD establishes a number of fundamental principles including strict timelines for the pricing and reimbursement (P&R) process. Our study focuses on the implementation of the Transparency Directive in Hungary with special focus on time-limits for P&R decisions. METHODS:
PHP27
IMPLEMENTATION OF THE TRANSPARENCY DIRECTIVE IN HUNGARY: SPECIAL FOCUS ON TIME LIMITS FOR PRICING AND REIMBURSEMENT DECISIONS
We analyzed official decisions in 103 P&R submissions (positive cases with decisions only) made by the National Health Insurance Fund Administration (NHIFA) between 2004 and 2010. Most of the cases belonged to pharmaceuticals with new active ingredients and without reimbursement at the time of submission. We excluded generic drugs and cases without P&R decision from the analysis. In order to determine the market access time we calculated the time period between the registration date of the drug by the European Medicines Agency (EMA) or by the National Institute of Pharmacy (NIP) and the P&R decision. RESULTS: The average time period from registration to P&R decision was 721 days (min: 46 days, max: 2696 days); from registration to P&R submission was 481 days (min: 1 days, max: 2581 days), from P&R submission to P&R decision was 214 days (min: 7 days, max: 990 days). Hungarian patients get access later to those medicines with centralized EMA registration compared with medicines with national registration procedure by NIP (average elapsed time from registration to positive decision was 827 days by EMA, 513 days by NIP). CONCLUSIONS: Periods needed for decisions are generally in accordance with the 90ϩ90 days recommendation of the TD. There is a positive change in pricing and reimbursement process in Hungary; decision procedure was shorter in 2010 than it was in 2004. Hungarian patients get new, better medicines later if the registration was done by EMA.
PHP28
REASONS FOR PROJECT DISCONTINUATION IN THE PHARMACEUTICAL INDUSTRY
Puig-Peiró R 1 , Mestre-Ferrandiz J 1 , Macdonald F 2 , Towse A 1 1 Office of Health Economics, London, UK, 2 F. Macdonald Consulting, London, UK OBJECTIVES: Drug development productivity has decreased over the past 10 years. The objectives are to a) better describe the reasons for discontinuations and b) help define the scale of the issue around discontinuing products and additional indications for reasons related to an anticipated lack of pricing and reimbursement flexibility. METHODS: A restricted and confidential survey to four pharmaceutical companies on their discontinued projects for lead and follow-on indications during the period 2005-2009. Reasons for discontinuation distinguished two major categories, 'technical' (including failure to meet safety or efficacy targets) and 'commercial' reasons. RESULTS: The four companies reported a total of 1,053 projects which had been active during the period 2005-2009. Of those, 51% were discontinued (nϭ541) by the end of 2009; 332 were lead indications and 209 were follow-on indications. About 72% of discontinuations for lead indications were for technical reasons. The pattern for follow-on indications is more complex. Technical reasons triggered a smaller proportion of discontinuations, presumably because many were addressed with the lead indication. However, a greater percentage of the discontinuations were after Phases II and III, implying higher costs to this point. Portfolio prioritisations and exiting the disease area accounted for 20% of discontinued projects. CONCLUSIONS: The results for lead indications reinforce previous results about the growing importance of non-technical i.e. commercial reasons as drivers for project discontinuations, around 20-25% in our sample. However, our results show for the first time an analysis for follow-on indications and where no comparison to previous literature is possible.
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